Clinical Trials Logo

Pompe Disease (Late-onset) clinical trials

View clinical trials related to Pompe Disease (Late-onset).

Filter by:

NCT ID: NCT00250939 Completed - Clinical trials for Pompe Disease (Late-onset)

A Study of rhGAA in Patients With Late-Onset Pompe Disease

Start date: February 2005
Phase: Phase 2
Study type: Interventional

Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The overall objective is to evaluate the safety, pharmacokinetics (PK) and efficacy of Myozyme treatment.

NCT ID: NCT00158600 Completed - Clinical trials for Pompe Disease (Late-onset)

A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

Start date: September 2005
Phase: Phase 3
Study type: Interventional

Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The overall objective is to evaluate the safety, efficacy, and pharmacokinetics (PK) of alglucosidase alfa treatment in patients with late-onset Pompe disease as compared to placebo.